<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033382</url>
  </required_header>
  <id_info>
    <org_study_id>12-02903</org_study_id>
    <nct_id>NCT02033382</nct_id>
  </id_info>
  <brief_title>Biomarkers in First Episode Schizophrenia</brief_title>
  <official_title>Biomarkers in First Episode Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will identify and evaluate relevant biomarkers and structural brain imaging for&#xD;
      understanding potential biological illness related mechanisms in medication-naïve subjects&#xD;
      with early psychosis before and after initiation of antipsychotic medication&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is currently unknown whether deterioration early in the course of psychotic illness&#xD;
      represents medication toxicity or the natural course of the illness. The study will help&#xD;
      clarify this issue in observing 70 schizophrenic patients before and after they are&#xD;
      prescribed an antipsychotic via standard of care.&#xD;
&#xD;
      In addition, schizophrenia is a heterogeneous disorder and a putative brain-derived&#xD;
      neurotrophic factor (BDNF) deficit, while possibly a common pathway, may not fully capture&#xD;
      the biological diversity-the supplemental biomarkers will allow us to perform a more&#xD;
      comprehensive assessment of factors contributing to clinical course. Taken together analysis&#xD;
      of these biomarkers in relation to clinical course and in relation to healthy subjects will&#xD;
      inform us about biological mechanisms contributing to illness onset, effects of antipsychotic&#xD;
      medication on these mechanisms, and the predictive value of the biomarkers for clinical&#xD;
      course. This information will provide the foundation for future early intervention trials&#xD;
      targeting biological mechanisms utilizing a personalized medicine approach.&#xD;
&#xD;
      The baseline visit for 70 schizophrenic patients and 70 healthy age and gender matched&#xD;
      controls consists of structural and functional MRI in addition to a blood draw for biomarkers&#xD;
      including BDNF, inflammation markers, DNA, oxidative stress, and folate status and&#xD;
      additionally a salivary cortisol sample collection. Biomarkers and imaging will be repeated&#xD;
      after 8 weeks of antipsychotic treatment in patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare biomarkers for inflammation, BDNF, oxidative stress, glucocorticoids and folate/methylation status in medication-naïve schizophrenia/schizophreniform subjects and matched healthy controls to identify illness-related factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Salivary Cortisol Levels</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Compare biomarkers at baseline and after 8 weeks of risperidone treatment in medication-naïve schizophrenia/schizophreniform subjects to identify treatment-related factors.&#xD;
Since Blood and Saliva was only collected from First Episode participants (FEP) at week 8 (not from healthy controls) these results only report the baseline and week 8 biomarker levels for FEP participants who completed week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Salivary Cortisol Levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare biomarkers for stress (salivary cortisol) in medication-naïve schizophrenia/schizophreniform subjects and matched healthy controls to identify illness-related factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Salivary Cortisol Levels</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>Compare salivary cortisol at baseline and after 8 weeks of risperidone treatment in medication-naïve schizophrenia/schizophreniform subjects to identify treatment-related factors.&#xD;
Since Blood and Saliva was only collected from First Episode participants (FEP) at week 8 (not from healthy controls) these results only report the baseline and week 8 biomarker levels for FEP participants who completed week 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Hippocampal Volumetric Integrity (HVI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare hippocampal volume in medication-naïve schizophrenia/schizophreniform subjects and healthy controls and examine whether biomarkers predict differences between groups in baseline hippocampal volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Performance</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Compare cognitive performance on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) in medication- naïve schizophrenia/schizophreniform subjects and healthy controls and examine whether biomarkers predict differences between groups in baseline cognitive performance. The composite score on the MCCB is calculated by the software using all tests administered. The composite score is a t-score assuming the mean score (50%) is the normative performance of the general population. The composite score ranges from 0-100 with a standard deviation of 10. A score greater than 50 implies a score better than the average population norm and a score less than 50 indicates performance worse than the general population norm.&#xD;
For schizophrenia subjects who complete 8 weeks of antipsychotic treatment, week 8 MATRICS testing results will be used to minimize the effect of psychosis on cognitive performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Change in Left Hippocampal Volume Integrity</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Compare hippocampal volume in medication-naïve schizophrenia/schizophreniform subjects before and after 8 weeks treatment with antipsychotic to assess evidence for early neurotoxicity.&#xD;
This outcome measure reports annualized rate of change in Left Hippocampal Volume Integrity (LHVI) because a few participants had a delay in their week 8 visit.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">165</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizophreniform Disorder</condition>
  <condition>Schizoaffective Disorder, Depressed Type</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Age and gender matched healthy controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Whole Blood&#xD;
&#xD;
        -  DNA&#xD;
&#xD;
        -  Saliva&#xD;
&#xD;
        -  Serum&#xD;
&#xD;
        -  Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be 70 patients, ages 15-40, with first episode schizophrenia or&#xD;
        schizophreniform disorder with onset before age 35 who are medication naive and do not meet&#xD;
        criteria for major depression or significant suicidal ideation or substance abuse (except&#xD;
        nicotine) and 70 age and gender matched healthy controls. Subjects will be recruited by&#xD;
        physicians in the Bellevue Hospital emergency room, outpatient clinic and on the Bellevue&#xD;
        psychiatric inpatient units as well as through the inpatient / outpatient services at&#xD;
        Shanghai Mental Health Center .&#xD;
&#xD;
        Potential subjects will be identified by clinicians and asked whether they would like to&#xD;
        speak to a researcher. Healthy subjects will be recruited through advertising by using a&#xD;
        flyer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female&#xD;
&#xD;
          2. Ages 15-40 years&#xD;
&#xD;
          3. Schizophrenia, any subtype or Schizophreniform disorder&#xD;
&#xD;
          4. Sufficient proficiency in English or Spanish to complete assessments (US)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major depression by the Diagnostic and Statistical Manual of Mental Disorders IV&#xD;
             criteria&#xD;
&#xD;
          2. Calgary Depression Scale for Schizophrenia (CDSS) score of 7 or greater.&#xD;
&#xD;
          3. Clinical Global Assessment of Severity of Suicidality of 3 (moderate) or greater.&#xD;
&#xD;
          4. Serious suicide attempt within three years&#xD;
&#xD;
          5. Treatment with an antipsychotic or antidepressant within the last six months&#xD;
&#xD;
          6. Active alcohol or other substance abuse or dependence within one month&#xD;
&#xD;
          7. Unstable medical illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <results_first_submitted>October 19, 2018</results_first_submitted>
  <results_first_submitted_qc>January 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2021</results_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Controls</title>
          <description>Age and gender matched healthy controls</description>
        </group>
        <group group_id="P2">
          <title>Patients</title>
          <description>Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Controls</title>
          <description>Age and gender matched healthy controls</description>
        </group>
        <group group_id="B2">
          <title>Patients</title>
          <description>Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.86" spread="6.40"/>
                    <measurement group_id="B2" value="25.19" spread="7.39"/>
                    <measurement group_id="B3" value="24.56" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biomarkers</title>
        <description>Compare biomarkers for inflammation, BDNF, oxidative stress, glucocorticoids and folate/methylation status in medication-naïve schizophrenia/schizophreniform subjects and matched healthy controls to identify illness-related factors.</description>
        <time_frame>Baseline</time_frame>
        <population>Not all biomarkers were available for analysis for all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Age and gender matched healthy controls</description>
          </group>
          <group group_id="O2">
            <title>Patients</title>
            <description>Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers</title>
          <description>Compare biomarkers for inflammation, BDNF, oxidative stress, glucocorticoids and folate/methylation status in medication-naïve schizophrenia/schizophreniform subjects and matched healthy controls to identify illness-related factors.</description>
          <population>Not all biomarkers were available for analysis for all subjects.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BDNF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.37" lower_limit="145.99" upper_limit="722.44"/>
                    <measurement group_id="O2" value="340.83" lower_limit="142.52" upper_limit="340.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thioredoxin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="492.33" lower_limit="324.17" upper_limit="637.67"/>
                    <measurement group_id="O2" value="420.17" lower_limit="323.58" upper_limit="609.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.44" lower_limit="61.14" upper_limit="265.52"/>
                    <measurement group_id="O2" value="125.13" lower_limit="69.76" upper_limit="211.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-Reactive Protein</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7610.07" lower_limit="6937.90" upper_limit="9025.92"/>
                    <measurement group_id="O2" value="7631.41" lower_limit="6778.62" upper_limit="9456.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 1B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.77" lower_limit="44.41" upper_limit="225.11"/>
                    <measurement group_id="O2" value="68.82" lower_limit="35.35" upper_limit="166.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.41" lower_limit="50.77" upper_limit="82.46"/>
                    <measurement group_id="O2" value="71.30" lower_limit="49.79" upper_limit="83.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Necrosis Factor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.03" lower_limit="74.28" upper_limit="103.94"/>
                    <measurement group_id="O2" value="93.60" lower_limit="76.02" upper_limit="105.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interferon gamma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.96" lower_limit="64.69" upper_limit="131.47"/>
                    <measurement group_id="O2" value="89.42" lower_limit="70.87" upper_limit="113.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glutamate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.00" lower_limit="92.00" upper_limit="121.60"/>
                    <measurement group_id="O2" value="111.00" lower_limit="98.20" upper_limit="128.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.32" lower_limit="79.33" upper_limit="141.65"/>
                    <measurement group_id="O2" value="134.32" lower_limit="86.67" upper_limit="198.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homocysteine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" lower_limit="4.44" upper_limit="5.38"/>
                    <measurement group_id="O2" value="4.83" lower_limit="4.53" upper_limit="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.28" lower_limit="9.83" upper_limit="17.75"/>
                    <measurement group_id="O2" value="15.08" lower_limit="11.27" upper_limit="20.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Salivary Cortisol Levels</title>
        <description>Compare biomarkers at baseline and after 8 weeks of risperidone treatment in medication-naïve schizophrenia/schizophreniform subjects to identify treatment-related factors.&#xD;
Since Blood and Saliva was only collected from First Episode participants (FEP) at week 8 (not from healthy controls) these results only report the baseline and week 8 biomarker levels for FEP participants who completed week 8.</description>
        <time_frame>Baseline and week 8</time_frame>
        <population>Analysis was done for first episode participants who completed both Baseline and Week 8 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Biomarkers at baseline prior to risperidone treatment in medication-naïve schizophrenia/schizophreniform subjects.</description>
          </group>
          <group group_id="O2">
            <title>Week 8</title>
            <description>Biomarkers at week 8 of risperidone treatment in medication-naïve schizophrenia/schizophreniform subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Salivary Cortisol Levels</title>
          <description>Compare biomarkers at baseline and after 8 weeks of risperidone treatment in medication-naïve schizophrenia/schizophreniform subjects to identify treatment-related factors.&#xD;
Since Blood and Saliva was only collected from First Episode participants (FEP) at week 8 (not from healthy controls) these results only report the baseline and week 8 biomarker levels for FEP participants who completed week 8.</description>
          <population>Analysis was done for first episode participants who completed both Baseline and Week 8 only.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-reactive protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7541.41" lower_limit="6647.32" upper_limit="9445.12"/>
                    <measurement group_id="O2" value="7627.60" lower_limit="6708.99" upper_limit="9474.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 1B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.81" lower_limit="34.82" upper_limit="153.33"/>
                    <measurement group_id="O2" value="57.01" lower_limit="28.18" upper_limit="168.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.34" lower_limit="50.02" upper_limit="93.98"/>
                    <measurement group_id="O2" value="65.79" lower_limit="51.16" upper_limit="82.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interferon gamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.26" lower_limit="73.44" upper_limit="117.90"/>
                    <measurement group_id="O2" value="98.14" lower_limit="61.71" upper_limit="124.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor necrosis factor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.60" lower_limit="75.75" upper_limit="107.69"/>
                    <measurement group_id="O2" value="89.45" lower_limit="71.25" upper_limit="109.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" lower_limit="2.60" upper_limit="4.55"/>
                    <measurement group_id="O2" value="4.75" lower_limit="3.76" upper_limit="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glutamate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" lower_limit="4.54" upper_limit="6.20"/>
                    <measurement group_id="O2" value="5.29" lower_limit="4.77" upper_limit="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" lower_limit="3.11" upper_limit="5.21"/>
                    <measurement group_id="O2" value="3.95" lower_limit="2.75" upper_limit="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homocysteine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" lower_limit="4.51" upper_limit="5.11"/>
                    <measurement group_id="O2" value="5.02" lower_limit="4.75" upper_limit="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDNF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465.98" lower_limit="145.23" upper_limit="1965.72"/>
                    <measurement group_id="O2" value="356.20" lower_limit="218.79" upper_limit="1040.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thioredoxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417.50" lower_limit="291.67" upper_limit="547.75"/>
                    <measurement group_id="O2" value="405.33" lower_limit="326.92" upper_limit="519.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.63" lower_limit="91.25" upper_limit="299.88"/>
                    <measurement group_id="O2" value="111.39" lower_limit="49.78" upper_limit="278.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Salivary Cortisol Levels</title>
        <description>Compare biomarkers for stress (salivary cortisol) in medication-naïve schizophrenia/schizophreniform subjects and matched healthy controls to identify illness-related factors.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Age and gender matched healthy controls</description>
          </group>
          <group group_id="O2">
            <title>Patients</title>
            <description>Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Salivary Cortisol Levels</title>
          <description>Compare biomarkers for stress (salivary cortisol) in medication-naïve schizophrenia/schizophreniform subjects and matched healthy controls to identify illness-related factors.</description>
          <units>µg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.88" lower_limit="3.19" upper_limit="7.51"/>
                    <measurement group_id="O2" value="6.56" lower_limit="4.18" upper_limit="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Salivary Cortisol Levels</title>
        <description>Compare salivary cortisol at baseline and after 8 weeks of risperidone treatment in medication-naïve schizophrenia/schizophreniform subjects to identify treatment-related factors.&#xD;
Since Blood and Saliva was only collected from First Episode participants (FEP) at week 8 (not from healthy controls) these results only report the baseline and week 8 biomarker levels for FEP participants who completed week 8.</description>
        <time_frame>Baseline and week 8</time_frame>
        <population>Analysis was done for first episode subjects who completed both Baseline and Week 8 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>salivary cortisol at baseline prior to risperidone treatment in medication-naïve schizophrenia/schizophreniform subjects.</description>
          </group>
          <group group_id="O2">
            <title>Week 8</title>
            <description>salivary cortisol at week 8 of risperidone treatment in medication-naïve schizophrenia/schizophreniform subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Salivary Cortisol Levels</title>
          <description>Compare salivary cortisol at baseline and after 8 weeks of risperidone treatment in medication-naïve schizophrenia/schizophreniform subjects to identify treatment-related factors.&#xD;
Since Blood and Saliva was only collected from First Episode participants (FEP) at week 8 (not from healthy controls) these results only report the baseline and week 8 biomarker levels for FEP participants who completed week 8.</description>
          <population>Analysis was done for first episode subjects who completed both Baseline and Week 8 only.</population>
          <units>µg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.41" lower_limit="1.89" upper_limit="9.17"/>
                    <measurement group_id="O2" value="4.36" lower_limit="2.37" upper_limit="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Hippocampal Volumetric Integrity (HVI)</title>
        <description>Compare hippocampal volume in medication-naïve schizophrenia/schizophreniform subjects and healthy controls and examine whether biomarkers predict differences between groups in baseline hippocampal volume.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Age and gender matched healthy controls</description>
          </group>
          <group group_id="O2">
            <title>Patients</title>
            <description>Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Hippocampal Volumetric Integrity (HVI)</title>
          <description>Compare hippocampal volume in medication-naïve schizophrenia/schizophreniform subjects and healthy controls and examine whether biomarkers predict differences between groups in baseline hippocampal volume.</description>
          <units>% of hippocampal volumetric integrity</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".9512" lower_limit=".8501" upper_limit=".9825"/>
                    <measurement group_id="O2" value=".9275" lower_limit=".8256" upper_limit=".9689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Performance</title>
        <description>Compare cognitive performance on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) in medication- naïve schizophrenia/schizophreniform subjects and healthy controls and examine whether biomarkers predict differences between groups in baseline cognitive performance. The composite score on the MCCB is calculated by the software using all tests administered. The composite score is a t-score assuming the mean score (50%) is the normative performance of the general population. The composite score ranges from 0-100 with a standard deviation of 10. A score greater than 50 implies a score better than the average population norm and a score less than 50 indicates performance worse than the general population norm.&#xD;
For schizophrenia subjects who complete 8 weeks of antipsychotic treatment, week 8 MATRICS testing results will be used to minimize the effect of psychosis on cognitive performance.</description>
        <time_frame>Baseline, week 8</time_frame>
        <population>Data provided only for subjects who completed assessments at both time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Age and gender matched healthy controls</description>
          </group>
          <group group_id="O2">
            <title>Patients</title>
            <description>Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Performance</title>
          <description>Compare cognitive performance on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) in medication- naïve schizophrenia/schizophreniform subjects and healthy controls and examine whether biomarkers predict differences between groups in baseline cognitive performance. The composite score on the MCCB is calculated by the software using all tests administered. The composite score is a t-score assuming the mean score (50%) is the normative performance of the general population. The composite score ranges from 0-100 with a standard deviation of 10. A score greater than 50 implies a score better than the average population norm and a score less than 50 indicates performance worse than the general population norm.&#xD;
For schizophrenia subjects who complete 8 weeks of antipsychotic treatment, week 8 MATRICS testing results will be used to minimize the effect of psychosis on cognitive performance.</description>
          <population>Data provided only for subjects who completed assessments at both time points.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline MCCB Composite Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.50" lower_limit="41" upper_limit="53"/>
                    <measurement group_id="O2" value="34" lower_limit="24.5" upper_limit="45.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 MCCB Composite Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.50" lower_limit="44.25" upper_limit="54"/>
                    <measurement group_id="O2" value="42.50" lower_limit="32.25" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Change in Left Hippocampal Volume Integrity</title>
        <description>Compare hippocampal volume in medication-naïve schizophrenia/schizophreniform subjects before and after 8 weeks treatment with antipsychotic to assess evidence for early neurotoxicity.&#xD;
This outcome measure reports annualized rate of change in Left Hippocampal Volume Integrity (LHVI) because a few participants had a delay in their week 8 visit.</description>
        <time_frame>Baseline, week 8</time_frame>
        <population>This analysis includes participants that completed both baseline and week 8 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Age and gender matched healthy controls</description>
          </group>
          <group group_id="O2">
            <title>Patients</title>
            <description>Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Change in Left Hippocampal Volume Integrity</title>
          <description>Compare hippocampal volume in medication-naïve schizophrenia/schizophreniform subjects before and after 8 weeks treatment with antipsychotic to assess evidence for early neurotoxicity.&#xD;
This outcome measure reports annualized rate of change in Left Hippocampal Volume Integrity (LHVI) because a few participants had a delay in their week 8 visit.</description>
          <population>This analysis includes participants that completed both baseline and week 8 visits.</population>
          <units>Percentage of standard hippocampal vol.</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004535" lower_limit="-0.0151" upper_limit="0.0350"/>
                    <measurement group_id="O2" value="-0.03027" lower_limit="-0.0817" upper_limit="0.00004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Healthy Controls</title>
          <description>Age and gender matched healthy controls</description>
        </group>
        <group group_id="E2">
          <title>Patients</title>
          <description>Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>BLURRED VISION</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="HYPERTENSION">Hypertension</sub_title>
                <description>BP sitting 130/100, standing 130/95</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <description>Patient reported blurred vision</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>646-754-4843</phone>
      <email>donald.goff@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

